How to help your patients find Qbrelis in stock: A provider's guide

How to Help Your Patients Find Qbrelis in Stock: A Provider's Guide

When patients depend on Qbrelis (Lisinopril oral solution, 1 mg/mL) and can't find it at their pharmacy, they often turn to their prescriber for help. This guide provides a structured workflow for locating Qbrelis stock, managing patient expectations, and implementing backup plans when supply is limited.

Understanding the Qbrelis Supply Challenge

Qbrelis is the only FDA-approved ready-to-use Lisinopril oral solution. Manufactured exclusively by Azurity Pharmaceuticals, it serves a critical but relatively small patient population — primarily pediatric patients with hypertension and adults with dysphagia or other conditions preventing tablet use.

The single-manufacturer model, combined with low retail pharmacy stocking rates, means that patients frequently encounter availability barriers. This is not always a formal "shortage" but rather a persistent distribution and stocking gap. For a clinical overview of current supply issues, see Qbrelis shortage: what providers need to know in 2026.

Step 1: Verify the Availability Issue

Before initiating a search, confirm the nature of the problem:

• Is the pharmacy out of stock temporarily? They may be able to reorder within days.
• Is the distributor unable to supply? This suggests a broader availability issue.
• Is it an insurance/PA denial? This requires a different intervention (see formulary section below).

Understanding the root cause will guide your next steps.

Step 2: Use MedFinder for Providers

MedFinder for Providers is a real-time pharmacy inventory search tool designed to help clinicians locate medications for their patients. To find Qbrelis:

1. Visit medfinder.com/providers
2. Search for "Qbrelis" or "Lisinopril oral solution"
3. Enter the patient's zip code
4. Review results showing pharmacies with current stock
5. Send the prescription to a pharmacy with confirmed availability

This eliminates the time-consuming process of calling pharmacies individually and reduces the risk of patients missing doses.

Step 3: Route to Specialty Pharmacies

Specialty pharmacies maintain broader inventories of niche medications and are significantly more likely to stock Qbrelis than retail chain pharmacies. Consider:

• Contacting the patient's insurance-preferred specialty pharmacy
• Checking with regional specialty pharmacies that focus on cardiovascular or pediatric medications
• Exploring mail-order specialty pharmacy options for ongoing supply

Step 4: Contact the Manufacturer

Azurity Pharmaceuticals maintains a medical affairs and customer service team that can provide:

• Current production and distribution status
• Pharmacy locator assistance
• Information on patient assistance programs
• Expected restock timelines during shortage periods

Step 5: Implement Alternative Therapy When Necessary

When Qbrelis cannot be located, have a documented backup plan ready for each affected patient. Recommended alternatives in order of clinical similarity:

1. Compounded Lisinopril oral suspension (1 mg/mL): Same active ingredient; 4-week refrigerated stability. Requires a compounding pharmacy.
2. Epaned (Enalapril oral solution, 1 mg/mL): FDA-approved alternative ACE inhibitor liquid. Dose conversion required.
3. Lisinopril tablets: For patients who can transition to solid oral dosage forms.
4. Captopril compounded solution: ACE inhibitor with BID-TID dosing; suitable when Lisinopril compounding unavailable.
5. Losartan compounded suspension: ARB class switch for ACE inhibitor-intolerant patients.

For detailed information on each alternative, see our clinical overview in the provider shortage guide and the patient-facing alternatives to Qbrelis.

Navigating Insurance and Prior Authorization

Common payer barriers for Qbrelis include:

• Step therapy requirements: Many plans require documented trial of Lisinopril tablets before covering the oral solution.
• Prior authorization: Nearly universal for Qbrelis given its cost ($690-$800 per bottle).
• Medical necessity documentation: Include diagnosis of dysphagia (ICD-10: R13.10-R13.19), pediatric age requiring liquid dosing, or documented inability to use tablet formulations.

Proactive PA submission — before the patient arrives at the pharmacy — reduces fill delays. Template letters documenting medical necessity for liquid ACE inhibitor therapy can streamline the process.

Setting Up a Proactive Workflow

To minimize patient disruptions, consider implementing these practice-level strategies:

• Flag Qbrelis patients in your EHR so staff can monitor refill timing and proactively check availability.
• Establish relationships with 2-3 pharmacies that reliably stock or can order Qbrelis.
• Pre-authorize alternative prescriptions that can be activated quickly if Qbrelis becomes unavailable.
• Educate patients on early refill strategies (7-10 days before running out) and direct them to MedFinder.com.
• Schedule follow-up within 2 weeks after any medication switch to verify blood pressure control.

Patient Resources to Share

Direct patients to these resources:

• MedFinder.com — Real-time pharmacy inventory search
• Qbrelis shortage update for patients
• How to find Qbrelis in stock near you
• How to save money on Qbrelis

For additional provider tools, visit MedFinder for Providers.